Bodi Envi blog, page 3
Plain, sourced writing on GLP-1 treatment: what the FDA-approved labels and the trials say, what compounded medication is and is not, what things cost, and how to choose a program.
- Guide
Nausea on semaglutide: what the label says and what helps
How often the Wegovy® label reports nausea and when, why it happens, what a provider may do, the steps published sources support, and when to seek care.
- Guide
Buying compounded GLP-1 medication online safely
What to verify before you order, as the FDA's BeSafeRx campaign and LegitScript describe it, the red flags the FDA names, and how to compare prices.
- Guide
Using the Bodi Envi patient portal
What Bodi Envi publishes about its patient portal at patient.bodienvi.com, logging in, messaging your care team, treatment monitoring and cancellation requests.
- Cost guide
Bodi Envi pricing and plans explained
The four terms for each compounded program, what every plan includes, why the price is the same at every dose, and what the refund policy says.
- Safety
Compounded GLP-1 safety: what to know before you start
What "not FDA-approved" means for compounded semaglutide and tirzepatide, how 503A pharmacies are regulated, the label warnings, and how to lower your risk.
- Guide
Semaglutide, pregnancy and fertility: what the label says
What the Wegovy® label says about pregnancy, stopping before a planned pregnancy and breastfeeding, and what the Zepbound® label says about oral contraceptives.
- Guide
Semaglutide, tirzepatide and sleep apnea
Zepbound® is FDA-approved for moderate to severe sleep apnea in adults with obesity and semaglutide is not. What the label and SURMOUNT-OSA found.
- Guide
Semaglutide vs tirzepatide: how the two compare
How semaglutide and tirzepatide differ in mechanism, dosing, side effects, trial results and cost at Bodi Envi, and why a licensed provider makes the choice.
- Guide
Semaglutide over time: what the trials measured
How STEP 1 was structured over 68 weeks, what it measured at the end and how widely results varied, and what the extension found after treatment stopped.
- Guide
GLP-1 side effects: what the labels report
Every side effect the Wegovy® and Zepbound® labels report, with frequencies, why the labels say they happen, what a provider may do, and when to seek care.
- Guide
What happens when you stop semaglutide or tirzepatide
What the STEP 1 extension and SURMOUNT-4 found after treatment stopped, what the labels say about missed doses, and how to raise stopping with a provider.
- Guide
How tirzepatide works
How tirzepatide acts on the GIP and GLP-1 receptors as the Zepbound® label describes it, what SURMOUNT-1 found over 72 weeks, and what a provider weighs.
- Guide
Tirzepatide and menopause
The Zepbound® label does not mention menopause. Who was in SURMOUNT-1 by sex and age, what a 2026 review says about sex and response, and what to ask.
- Guide
Tirzepatide side effects per the Zepbound® label
The side effects the Zepbound® label reports for tirzepatide by dose, when they occur, why, what a provider may do and when to seek care.
- Guide
Traveling with tirzepatide
What the Zepbound® label allows at room temperature, what the TSA says about medication at screening, and how to plan doses across a trip.
- Guide
Eating too little on a GLP-1 medication
What the labels warn about dehydration and kidney injury from reduced intake, what 2026 reviews report on meal size and muscle, and when to tell your provider.
- Guide
Eating well on tirzepatide, including plant based
What the Zepbound® label says about diet, what the Dietary Guidelines for Americans recommend, and what published reviews say about plant based eating.
- Guide
Not losing weight on tirzepatide: what to consider
How much results varied in SURMOUNT-1, what the Zepbound® label says about escalation and dose, what predicts response, and what to raise with a provider.
Start with an online assessment.
Answer a few questions about your health and goals. A licensed provider reviews your answers and decides whether treatment is appropriate for you.